EU Healthcare Biotech Policy Priorities for SMEs
Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing […]
Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing […]
Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Join The World's Largest Global Biotech Partnering Experience From the 10th to June 18th takes place […]
EuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China, and how this impacts both the EU and US. We […]
Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines, the European Commission will facilitate cooperation between actors in the supply […]
The 17th edition of the International Conference on Renewable Resources & Biorefineries will take place in Aveiro, Portugal from Monday 6 Sept until Wednesday 8 Sept, 2021. Based on the previous […]
The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important […]
Germany's largest biotech event, the German Biotechnology Days 2021 (Deutsche Biotechnologietage, DBT), will take place on 20th and 21st September in Stuttgart. With over 800 participants, […]
Sustainability in industrial biotech innovations: life cycle assessment and beyond Get ready for EFIB 2021 by attending the kick-off webinar “Sustainability in Industrial biotech innovations: Life Cycle […]
The European Biotech Week celebrates biotechnology, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech […]
BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe.
EuropaBio’s launch meeting for Biotech Week will share how science finds its way to an end use, whether it is a new medicine, or a product developed using new scientific processes.
The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life science and biotechnology sector in the EU.